2. Academic Validation
  3. Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization

Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization

  • Nat Commun. 2025 Aug 12;16(1):7430. doi: 10.1038/s41467-025-62645-6.
Zhijiao Zhang # 1,  Xiaoyu Shi # 1,  Ting Wu # 2,  Zhuhan He 3,  Ruipeng Liang 1,  Wenjie Ye 2,  Zhenkun Wu 2,  Hui Liao 2,  Fengxin Zheng 2,  Qian Yang 1,  Zean Zhao 2,  Yongjun Chen 2,  Zhen Gao 1,  Shuo Wang 1,  Mei Wang 1,  Zhenqian Wang 1,  Danhui Qi 1,  Mingyu Yang 1,  Shujing Xu 1,  Youzhao Wang 3,  Tong Zhao 1,  Javier Egea 4,  Xinyong Liu 5,  Jianxin Pang 6,  Fan Yi 7,  Peng Zhan 8
Affiliations

Affiliations

  • 1 State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P. R. China.
  • 2 NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, P. R. China.
  • 3 Department of Pharmacology; Shandong University School of Medicine, Jinan, P. R. China.
  • 4 Unidad de Investigación, Hospital Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
  • 5 State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P. R. China. xinyongl@sdu.edu.cn.
  • 6 NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, P. R. China. pjx@smu.edu.cn.
  • 7 Department of Pharmacology; Shandong University School of Medicine, Jinan, P. R. China. fanyi@sdu.edu.cn.
  • 8 State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P. R. China. zhanpeng1982@sdu.edu.cn.
  • # Contributed equally.
PMID: 40790034 DOI: 10.1038/s41467-025-62645-6
Abstract

Developing anti-gout medications that simultaneously reduce uric acid and exert anti-inflammatory effects represents a critical breakthrough for managing gout progression. Natural products with polypharmacological properties offer promising leads for drug discovery. In this study, β-carboline-1-propionic acid, a bioactive constituent of Eurycoma longifolia Jack, served as the starting point for drug design. Guided by a dual-target pharmacophore model, we design and synthesize 64 derivatives. Through systematic screening, 32 emerges as a drug candidate, demonstrating potent uric acid-lowering activity in male hyperuricemia mouse models (efficacy comparable to febuxostat and superior to lesinurad and benzbromarone) by inhibiting key urate transporters. In a male rat model of acute gouty arthritis, 32 mitigates NOD-like Receptor protein 3 inflammasome-mediated inflammation. Notably, 32 exhibits enhanced safety compared to control drugs. This study exemplifies a natural product-inspired, dual-mechanism drug discovery approach, showcasing the potential of a rational polypharmacology and thus offering therapeutic opportunities for gout management.

Figures
Products